Login
ZIOPHARM Oncology NASDAQ: ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology
| Name | ZIOPHARM Oncology |
| Ticker | ZIOP |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
|
Price
52W Low/High |
3.45
2.09 / 5.60 |
| Momentum | Sharp Down |
| Market cap | 739 M |
| 1Y Total Return |
27.31%
Below Average |
| 1Y Volatility |
81.13%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology
Details
| Ticker | ZIOP |
| Name | ZIOPHARM Oncology |
| ISIN | US98973P1012 |
| CUSIP | 98973P101 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 4/14/21
| Close Price | 3.45 |
| 52W Low/High | 2.09 / 5.60 |
| Market cap | 739 M |
| 1Y Total Return |
27.31%
Below Average |
| 1Y Volatility |
81.13%
High Risk |
| Beta | 1.96 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | - |
| Cash from Op. / Cur. Liabilities | -3.10 |
| Diluted Earnings / Share | -0.38 |
| ROE | - |
| ROIC | -542.3% |
| Price / Revenue | - |
| Price / Book | 5.8 |
| Price / CF | -12.7 |
| Current Ratio | 7.1 |
| Cur.Liabilities / Tot.Liabilities | 0.8 |
| Financial Leverage | 0.03 |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
0
|
0
|
0
|
6
|
7
|
4
|
|
| Gross Profit |
-
|
-
|
0
|
6
|
7
|
4
|
|
| R&D |
53
|
38
|
34
|
45
|
158
|
107
|
|
| EBITDA |
-79
|
-117
|
155
|
-54
|
-165
|
-120
|
|
| Operating Income |
-80
|
-58
|
-54
|
-53
|
-165
|
-120
|
|
| Net Income exc. Extra |
-
|
-
|
154
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
210
|
168
|
144
|
137
|
130
|
125
|
|
| EPS exc. Extra |
-0.38
|
-0.70
|
0.96
|
-0.53
|
-1.32
|
-0.96
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
146
|
109
|
95
|
106
|
106
|
154
|
|
| Cash, Eq & Invt ShortTerm |
115
|
80
|
62
|
71
|
81
|
141
|
|
| Total Current Assets |
131
|
105
|
84
|
91
|
105
|
153
|
|
| Total Non-Current Assets |
16
|
4
|
11
|
15
|
1
|
1
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
22
|
14
|
9
|
58
|
58
|
66
|
|
| Total Current Liabilities |
18
|
13
|
9
|
21
|
16
|
18
|
|
| Long Term Debt |
4
|
2
|
0
|
38
|
43
|
48
|
|
| Shareholder equity |
124
|
95
|
86
|
-97
|
-77
|
87
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-57
|
-41
|
-49
|
-55
|
-58
|
0
|
|
| Depreciation |
1
|
1
|
1
|
0
|
0
|
0
|
|
| Cash from Investing |
-10
|
0
|
0
|
-1
|
-1
|
0
|
|
| Capex |
10
|
0
|
0
|
1
|
1
|
0
|
|
| Cash from Financing |
102
|
59
|
40
|
45
|
-1
|
98
|
|
| Stock Issued |
102
|
59
|
-1
|
45
|
-1
|
98
|
|
| Debt (LT) Issued |
0
|
0
|
47
|
0
|
0
|
0
|
|
| Free Cash Flow |
-84
|
-116
|
142
|
-50
|
-168
|
-114
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
94,004.1%
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
7.1
|
8.4
|
8.9
|
4.4
|
6.6
|
8.4
|
|
| Financial Leverage D/E |
0.03
|
0.02
|
0.00
|
-
|
-
|
0.00
|
|
| Return on Capital Avg |
-542.3%
|
-582.7%
|
825.1%
|
-471.7%
|
-8,035.8%
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-2,441.7%
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available